Uetz Quoted in MarketScreener About Expected Surge of Bankruptcy Filings Due to Coronavirus Fallout
02 April 2020
Partner Ann Marie Uetz was quoted in The Wall Street Journal article, “Bankruptcy Lawyers Gear Up for Surge in Filings Due to Coronavirus Fallout,” about the anticipated increase in chapter 11 bankruptcy filings due to the disruption caused by the coronavirus. The speed of the filings is likely to depend on how long industry sectors are shut down.
Uetz said many manufacturers and automotive suppliers have been hit by the coronavirus outbreak. Lawyers are “working overtime” to guide them through interruptions in their supply chains and customer demands and in some instances working to help them avoid bankruptcy.
Uetz said many manufacturers and automotive suppliers have been hit by the coronavirus outbreak. Lawyers are “working overtime” to guide them through interruptions in their supply chains and customer demands and in some instances working to help them avoid bankruptcy.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”